<p>Bengaluru: Apollo AyurVAID, a National Accreditation Board for Hospitals and Healthcare Providers or NABH-accredited, ayurveda hospital network of the Apollo Group, is looking to expand pan-India this year. Currently, the company operates 12 hospitals across South India, Delhi, and Almora.</p>.<p>“We have multiple things. One is that more hospitals are coming up across India this year. We expect three to four more cities will be added this year. We also want to go deeper into Bengaluru, Chennai, etc. We are looking at Navi Mumbai, Pune, Hyderabad, Kolkata thereby covering all the major metros in the country,” Rajiv Vasudevan, Founder, MD, and CEO, Apollo AyurVAID told <em>DH</em>.</p>.<p>By the end of FY26, the company aims to expand its network to 18 hospitals, and 1 clinic. The bed strength will nearly double from the current 185 to 350 in this year. It is aiming to reach 1,000 beds by 2028.</p>.<p>The company is also getting into therapeutic wellness, and the entire area of digital data, AI, and ML-enabled personalised healthcare segment. “We are going to leverage the data we have in our healthcare services,” he said.</p>.<p>An alumnus of IIM Calcutta and NIT Calicut, Mr. Vasudevan began his professional journey as a scientist at ISRO’s Vikram Sarabhai Space Centre and later held leadership roles at Godrej & Boyce and Motorola India. He founded the ayurveda chain in 2005, and sold around 60% to Apollo Group three years ago to leverage the strength of the large hospital chain in the country. As a majority partner in the network, Apollo Group will fund the future expansion, he said.</p>.Adani's Mumbai Airport inks $750 mn deal with Apollo-led investor group.<p>Apollo AyurVAID follows a model of integrative care, where Ayurveda works alongside modern medicine to deliver comprehensive, patient-centered care. With the help of Apollo Group, the company now plans to explore newer areas. Integrating ayurveda and allopathy, the company intends to provide holistic care for patients across specialties such as neurology, oncology, nephrology, obstetrics and gynaecology, metabolic health, and gastroenterology with a focus on adjuvant therapy, palliative care, rehabilitation, and primary intervention.</p>.<p>“Apollo has been a very strong partner in the journey over the last two and a half years, and they have continued to invest after the initial investment that they have brought in. So that is how we have grown. We have a three-year roadmap, and Apollo is a part of that overall journey. We are very much on track,” Vasudevan explained.</p>.<p>Apollo AyurVAID has also forayed into the ayurvedic product segment. The new portfolio spans classical formulations, OTC products, and medical foods, crafted to meet the growing demand for safe, clinically validated offerings. Apollo AyurVAID’s product range features clinically proven formulations that are certified safe by NABL-accredited laboratories on presence of heavy metals, aflatoxins, microbial content, etc., as applicable for different product types. These products will be available across Apollo AyurVAID’s hospitals and clinics, the company’s website, Apollo Pharmacies, Apollo 24x7 and major e-commerce platforms. The classical and OTC product range are branded ‘AyurVAID’ while the dietary supplements are branded ‘AvestaAyurVAID’.</p>.<p>Apollo AuyurVAID clocked a revenue of Rs 32 crore in FY25 and aims to achieve a revenue target of Rs 100 crore in the next 12-18 months.</p>
<p>Bengaluru: Apollo AyurVAID, a National Accreditation Board for Hospitals and Healthcare Providers or NABH-accredited, ayurveda hospital network of the Apollo Group, is looking to expand pan-India this year. Currently, the company operates 12 hospitals across South India, Delhi, and Almora.</p>.<p>“We have multiple things. One is that more hospitals are coming up across India this year. We expect three to four more cities will be added this year. We also want to go deeper into Bengaluru, Chennai, etc. We are looking at Navi Mumbai, Pune, Hyderabad, Kolkata thereby covering all the major metros in the country,” Rajiv Vasudevan, Founder, MD, and CEO, Apollo AyurVAID told <em>DH</em>.</p>.<p>By the end of FY26, the company aims to expand its network to 18 hospitals, and 1 clinic. The bed strength will nearly double from the current 185 to 350 in this year. It is aiming to reach 1,000 beds by 2028.</p>.<p>The company is also getting into therapeutic wellness, and the entire area of digital data, AI, and ML-enabled personalised healthcare segment. “We are going to leverage the data we have in our healthcare services,” he said.</p>.<p>An alumnus of IIM Calcutta and NIT Calicut, Mr. Vasudevan began his professional journey as a scientist at ISRO’s Vikram Sarabhai Space Centre and later held leadership roles at Godrej & Boyce and Motorola India. He founded the ayurveda chain in 2005, and sold around 60% to Apollo Group three years ago to leverage the strength of the large hospital chain in the country. As a majority partner in the network, Apollo Group will fund the future expansion, he said.</p>.Adani's Mumbai Airport inks $750 mn deal with Apollo-led investor group.<p>Apollo AyurVAID follows a model of integrative care, where Ayurveda works alongside modern medicine to deliver comprehensive, patient-centered care. With the help of Apollo Group, the company now plans to explore newer areas. Integrating ayurveda and allopathy, the company intends to provide holistic care for patients across specialties such as neurology, oncology, nephrology, obstetrics and gynaecology, metabolic health, and gastroenterology with a focus on adjuvant therapy, palliative care, rehabilitation, and primary intervention.</p>.<p>“Apollo has been a very strong partner in the journey over the last two and a half years, and they have continued to invest after the initial investment that they have brought in. So that is how we have grown. We have a three-year roadmap, and Apollo is a part of that overall journey. We are very much on track,” Vasudevan explained.</p>.<p>Apollo AyurVAID has also forayed into the ayurvedic product segment. The new portfolio spans classical formulations, OTC products, and medical foods, crafted to meet the growing demand for safe, clinically validated offerings. Apollo AyurVAID’s product range features clinically proven formulations that are certified safe by NABL-accredited laboratories on presence of heavy metals, aflatoxins, microbial content, etc., as applicable for different product types. These products will be available across Apollo AyurVAID’s hospitals and clinics, the company’s website, Apollo Pharmacies, Apollo 24x7 and major e-commerce platforms. The classical and OTC product range are branded ‘AyurVAID’ while the dietary supplements are branded ‘AvestaAyurVAID’.</p>.<p>Apollo AuyurVAID clocked a revenue of Rs 32 crore in FY25 and aims to achieve a revenue target of Rs 100 crore in the next 12-18 months.</p>